Código QR (código de barras bidimensional)

Disruptive technology and hemophilia care: The multiple impacts of emicizumab

Abstract Emicizumab, a bispecific antibody mimicking the action of factor VIII (FVIII), is currently the first and only approved and increasingly accessible disruptive treatment option for hemophilia A, a disease so far mainly treated with frequent intravenous infusions of FVIII concentrates or bypa...

תיאור מלא

שמור ב:
Principais autores: Cedric Hermans, Mike Makris
פורמט: Artigo
שפה:Inglês
יצא לאור: Elsevier 2021-05-01
סדרה:Research and Practice in Thrombosis and Haemostasis
נושאים:
care
disruptive technology
emicizumab
hemophilia
inhibitor
nonreplacement therapy
גישה מקוונת:https://doi.org/10.1002/rth2.12508
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים